Pretreatment integrase strand transfer inhibitor resistance in Tianjin,China  

作　　者：Huan Xia Zhangwen Ge Defa Zhang Yue Wu Ping Ma 

机构地区：[1]Department of Infectious Diseases,Tianjin Second People’s Hospital,Tianjin 300192,China [2]Department of Laboratory Medicine,Guizhou Provincial People’s Hospital,Affiliated Hospital of Guizhou University,Guiyang,Guizhou 550499,China

出　　处：《Chinese Medical Journal》2023年第22期2735-2737,共3页中华医学杂志（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.82002136 and 82260658);the Health Science and Technology Project of Tianjin Health Commission(Nos.TJWJ2021MS033,ZC20037);the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-059B);the National Major Scientific and Technological Special Project during the Thirteenth Five-year Plan Period(Grant No.2018ZX10302104);the Science and Technology Project of Guizhou Province(qian ke he foundation-ZK[2023]general 215)

摘　　要：Human immunodeficiency virus(HIV)infection is a significant and pressing concern for public health worldwide.[1]Midway through the 1990s,the widespread use of antiretroviral therapy(ART)has resulted in a significant paradigm shift in the management of HIV infection,thereby altering its prognosis from a lifethreatening disease to a chronic and managed health condition.According to previous studies,people who are living with HIV(PLWH)that are on current ART have shown a decrease in both the morbidity and mortality associated with HIV infection,along with a decreased risk of transmitting the virus to others.

关 键 词：INFECTION MORTALITY prognosis 

分 类 号：R512.91[医药卫生—内科学]